Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4005130 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| LY4005130 | EXPERIMENTAL | LY4005130 administered intravenously (IV) |
| Placebo | PLACEBO_COMPARATOR | Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY4005130 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Have severe Alopecia Areata (AA) that meets all of the following criteria: * Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score * The duration of the current episode of severe AA is at least 6 months and does not excee...
LY4005130 is an investigational small molecule being developed by Eli Lilly and Company for dermatology indications. It is in Phase 2 clinical development for alopecia areata and vitiligo, two immune-related conditions affecting the skin and hair. It has not been approved by any regulatory agency and remains under clinical study.
LY4005130 is being studied for the treatment of alopecia areata, an autoimmune hair loss condition, and vitiligo, including non-segmental vitiligo. Both are dermatologic conditions under Phase 2 investigation. No approved use has been established for LY4005130, and it is available only through clinical trials.
LY4005130 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 2 clinical program evaluating the small molecule in alopecia areata and vitiligo.
LY4005130 is in Phase 2 clinical development. Two Phase 2 trials are currently recruiting, one in non-segmental vitiligo and one in severe alopecia areata. The drug is investigational and has not received FDA approval for any indication.
LY4005130 is being evaluated in two recruiting Phase 2 trials. NCT07533019 is a placebo-controlled study in adults with non-segmental vitiligo enrolling 66 participants across the United States, Belgium, Canada, China, and Poland. NCT07533006 is a placebo-controlled study in adults with severe alopecia areata enrolling 60 participants across the United States, Canada, China, Netherlands, Poland, South Korea, and the United Kingdom.
Yes. Both Phase 2 trials of LY4005130 are randomized, double-blind, and placebo-controlled. NCT07533019 enrolls 66 adults with non-segmental vitiligo, and NCT07533006 enrolls 60 adults with severe alopecia areata. Both studies require participants to be at least 18 years of age and are currently recruiting.